Floatz logo

Telaglenastat

Blasts 20-30 Percent of Bone Marrow Nucleated Cells

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

33 Active assets in the Blasts 20-30 Percent of Bone Marrow Nucleated Cells cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
University of Southern California
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BB
TACROLIMUS
Fred Hutchinson Cancer Center
Phase 2BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB

View all 50 →

Same molecule, other indications

Telaglenastat is also rated in:

Metastatic Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →